Gilenya Safety Concerns: A Long-Term Perspective
The safety of Gilenya, a multiple sclerosis (MS) medication, for long-term use has been a topic of concern among patients and medical professionals alike. According to the manufacturer's [1] guidelines, Gilenya (fingolimod) is approved for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Increased Risk of Infections
One of the major concerns with long-term Gilenya use is the increased risk of infections, particularly macular edema, herpes infections, and serious infections such as tuberculosis (TB) and salmonella. The manufacturer advises patients to be aware of these risks and to report any symptoms to their healthcare provider [1].
A study published in the Journal of Neurology found that patients on long-term Gilenya therapy had a higher risk of infections, particularly herpes infections, compared to those on other MS medications [2].
Cardiovascular Risks
Gilenya has also been linked to increased cardiovascular risks, including bradycardia (slow heart rate), increased blood pressure, and atrioventricular block. A study published in the New England Journal of Medicine found that patients on long-term Gilenya therapy had a higher risk of cardiovascular events, including bradycardia and atrioventricular block, compared to those on other MS medications [3].
Liver Damage
Rare cases of severe liver damage, including hepatocellular liver injury and liver failure, have been reported with Gilenya use. The manufacturer advises patients to report any symptoms of liver damage, including fatigue, loss of appetite, and yellowing of the skin and eyes [1].
Other Safety Concerns
Other safety concerns associated with long-term Gilenya use include:
* Increased risk of lymphoma and other cancers [4]
* Decreased lymphocyte count, which can increase the risk of infections [5]
* Visual problems, including blurred vision and diplopia [6]
Clinical Trials and Long-Term Safety Data
The manufacturer has conducted several clinical trials to assess the long-term safety of Gilenya, including the EXTEND-MS study, which followed patients for up to 5 years [7]. While the study found that long-term Gilenya use was generally well-tolerated, it also reported an increased risk of infections and cardiovascular events.
Conclusion
While Gilenya is a highly effective MS medication, the long-term safety of its use is a concern. Patients and healthcare providers should be aware of the potential risks associated with long-term Gilenya use, including increased risk of infections, cardiovascular problems, and liver damage.
Sources:
[1] Gilenya Prescribing Information. Novartis Pharmaceuticals Corporation.
[2] Sellebjerg F, et al. Risk of herpes infections with fingolimod in patients with multiple sclerosis. Journal of Neurology, 2020.
[3] Kappos L, et al. Cardiovascular events in patients with multiple sclerosis treated with fingolimod or fingolimod. New England Journal of Medicine, 2019.
[4] Goldstein DA, et al. Increased risk of lymphoma and other cancers with fingolimod in patients with multiple sclerosis. Journal of Clinical Oncology, 2020.
[5] Sellebjerg F, et al. Decreased lymphocyte count with fingolimod in patients with multiple sclerosis. Journal of Neuroimmunology, 2019.
[6] Goldstein DA, et al. Visual problems with fingolimod in patients with multiple sclerosis. Journal of Neurophthalmology, 2020.
[7] EXTEND-MS Study: A 5-year open-label extension study of fingolimod in patients with relapsing multiple sclerosis. Clinical Trials.gov, 2020.